FDA WARNING_LETTER - Replication Medical Inc

The FDA issued a Warning Letter to Replication Medical, Inc. concerning their EnGuard? Vessel Guard, which was found to be marketed with claims outside its 510(k) clearance. The device was cleared with limitations for use as a cover for vessels following anterior vertebral surgery, explicitly excluding claims related to reducing adhesion formation. However, the firm's White Paper and product brochure contained claims suggesting adhesion barrier functions, such as "preventing fibroblast penetration" and "facilitating mobilization of necessary tissues, organs, and vessels." The FDA determined these claims constituted a new intended use (21 CFR 807.81(a)(3)(ii)), classifying the device as a Class III device requiring a Premarket Approval Application (PMA). Consequently, the device was deemed adulterated under section 501(f)(1)(B) of the Act for lacking an approved PMA or Investigational Device Exemption (IDE), and misbranded under section 502(o) for failure to submit a 510(k) notification for the new intended use. Replication Medical was instructed to immediately cease disseminating these promotional materials and submit a written response within 15 working days detailing their corrective actions. Failure to comply could result in regulatory actions including seizure, injunction, or civil money penalties.